Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557097 | 1.00 | MGLL (0.43) | MGLLRAB9AGAAHSD11B1HSP90AA1 | |
| SCHEMBL29556753 | 0.86 | PDCD1LG2 (0.36) | MGLLHSP90AA1 | |
| SCHEMBL23067458 | 0.86 | PDCD1LG2 (0.36) | MGLLHSP90AA1 | |
| SCHEMBL14885099 | 0.82 | HPGD (0.52) | MGLLRAB9AHSD11B1TDP1 | |
| SCHEMBL17424954 | 0.78 | L3MBTL3 (0.61) | MBTD1TP53BP1L3MBTL3L3MBTL1 | |
| SCHEMBL15495402 | 0.78 | L3MBTL3 (0.56) | MGLLRAB9AL3MBTL3L3MBTL1 | |
| SCHEMBL23079257 | 0.77 | SMN1; SMN2 (0.46) | MGLLRAB9A | |
| SCHEMBL23067271 | 0.76 | HSP90AA1 (0.57) | MGLLHSP90AA1MAPK14MET | |
| SCHEMBL29556773 | 0.76 | HSP90AA1 (0.57) | MGLLHSP90AA1MAPK14MET | |
| SCHEMBL9356625 | 0.76 | HSP90AA1 (0.57) | RAB9AHSP90AA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028404-A2 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Tennor Therapeutics Limited (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-11040987-B2 | Penam derivatives for treating bacterial infections | TENNOR THERAPEUTICS LIMITED (CN) | 2021-06-22 | — | — | US | disclosed |
| WO-2021048613-A2 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-18 | — | — | WO | disclosed |
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | BPGM, BLVRB, PREP | MGLL 949/4885RAB9A 1446/4885GAA 74/4885 |
| US-11040987-B2 | Penam derivatives for treating bacterial infections | BPGM, BLVRB, PREP | MGLL 949/4885RAB9A 1446/4885GAA 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.